Bristol-Myers Squibb Option Alert: Jan 16 $55 Puts at the Bid: 1000 vs 2166 OI

Bristol-Myers Squibb Option Alert: Jan 16 $55 Puts at the Bid: 1000 @ $5.5 vs 2166 OI; Ref=$54.76

Bristol-Myers Squibb (NYSE:BMY) Stock

Bristol-Myers Squibb

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

EXEL

Biotech

News

Health Care

Buybacks

Movers

Trading Ideas

General

Exelixis reaffirmed its 2025 sales guidance of $2.15-$2.25 billion and reported sustained long-term efficacy for Cabometyx in advanced renal cell carcinoma.

Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?

BristolMeyersSquibb.Courtesyof.02-LVL-Exterior-Sign-101520-media

Large Cap

Bristol Myers&#39; Opdivo improved overall survival in resectable NSCLC, per final Phase 3 data. The study confirms its benefit when combined with chemotherapy.

Bristol Myers Cancer Drug Opdivo In Combination With Chemo Shows Improved Overall Survival In Certain Patients With Lung Cancer

Pfizer_shutterstock2

Dividends

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Wall Street&#39;s Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb Co

BRISTOL-MYERS SQUIBB $2PR by Bristol-Myers Squibb Co.

On Friday, Exelixis, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) authorized repurchasing up to an additional $500 million of the company&#8217;s common stock before <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43868849/exelixis-announces-a-newly-authorized-500-million-stock-repurchase-program" rel="noreferrer noopener">December 31, 2025</a>.
Exelixis plans to complete the $500 million stock repurchase program, announced in August 2024, in the second quarter of 2025 and commence stock repurchases under the newly authorized stock repurchase program thereafter.
As of the end of fiscal year 2024, Exelixis has returned over $1.2 billion to shareholders through these programs.
Earlier this month, Exelixis reported fourth-quarter adjusted EPS of 55 cents, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of 43 cents</a>. The cancer-focused company reported sales of $566.75 million, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43640071/exelixis-announces-fourth-quarter-and-fiscal-year-2024-financial-results-and-provides-corporate-up" rel="noreferrer noopener">consensus of $563.42 million</a>.
Exelixis reaffirmed its 2025 sales guidance of $2.15 billion-$2.25 billion versus consensus of $2.24 billion.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42488323/drug-price-hikes-unsupported-by-evidence-cost-us-815-million-icer-report" rel="noreferrer noopener">Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report</a>
Recently, Exelixis announced the final results from the phase 3 CheckMate -9ER pivotal trial evaluating Cabometyx&nbsp;(cabozantinib) in combination with Bristol-Myers Squibb &amp; Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Opdivo&nbsp;(nivolumab) versus sunitinib for patients with previously untreated advanced renal cell carcinoma (RCC).
After more than five years of follow-up, the findings demonstrated that the efficacy benefits of Cabometyx&nbsp;in combination with Opdivo were sustained long-term.
At a median follow-up of 67.6 months, Cabometyx, in combination with Opdivo, improved progression-free survival and overall survival compared with Pfizer Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Sutent (sunitinib) in the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43756537/exelixis-announces-final-five-year-follow-up-results-from-checkmate-9er-trial-evaluating-cabometyx" rel="noreferrer noopener">intent-to-treat population</a>.
A subgroup analysis by the International Metastatic RCC Database Consortium (IMDC) risk showed PFS and objective response rates favored Cabometyx in combination with Opdivo versus sunitinib regardless of the IMDC risk group.
In January, Exelixis announced that its supplemental New Drug Application (sNDA) for cabozantinib for adults with previously treated advanced pancreatic neuroendocrine and extra-pancreatic tumors will no longer be discussed at the FDA&#8217;s Oncologic Drugs Advisory Committee meeting. The sNDA remains under consideration by the FDA and has a Prescription Drug User Fee Act action <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b42896345/exelixis-provides-update-on-oncologic-drugs-advisory-committee-meeting-for-cabozantinib-cabometyx-" rel="noreferrer noopener">date of April 3</a>.
Price Action: EXEL stock is up 3.42% at $36.29 at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43888652/trump-medias-strategic-fund-set-to-fuel-mergers-and-acquisitions" target="_blank" rel="noreferrer noopener">Trump Media&#8217;s Strategic Fund Set To Fuel Mergers And Acquisitions: Details</a></li>
</ul>

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that BioArctic and its partner Bristol Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) have received clearance from the U.S. Federal Trade Commission (FTC) for BioArctic to out-license its PyroGlutamate-amyloid-beta (PyroGlu-Aβ) antibody program to Bristol Myers Squibb.&nbsp;Closing of the agreement has been completed and BioArctic will receive an upfront payment of USD 100 million.

BRCTF

BioArctic And Bristol Myers Squibb Finalize $100M Licensing Deal For PyroGlu-Aβ Antibody Program After U.S. Antitrust Clearance

On Wednesday, Bristol Myers Squibb&nbsp;&amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) announced the final analysis of overall survival (OS) from the Phase 3 CheckMate -816 study, which evaluated&nbsp;Opdivo (nivolumab) in combination with platinum-doublet chemotherapy as a neoadjuvant treatment for adult patients with resectable non-small <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43808682/bristol-myers-squibb-announces-opdivo-plus-chemotherapy-as-the-first-and-only-neoadjuvant-only-imm" rel="noreferrer noopener">cell lung cancer (NSCLC)</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43774882/donald-trumps-tax-cut-could-add-46-trillion-to-deficit-says-robert-reich-emphasizing-48-billion-relief-for-top-100-us-firms-via-corporate-tax-cuts" rel="noreferrer noopener">Trump&#8217;s Tax Cut Could Add $4.6 Trillion To Deficit, With $48 Billion Tax Relief For Top 100 Firms: Robert Reich</a>
The results showed a statistically significant and clinically meaningful improvement in overall survival, a key secondary endpoint, compared to neoadjuvant chemotherapy alone.
The results build on the previously reported primary endpoints of event-free survival (EFS) and pathological complete response (pCR), which also met statistical significance.
The safety profile of&nbsp;Opdivo&nbsp;in combination with chemotherapy was consistent with previously reported studies, with no new safety signals observed.
&#8220;The final analysis of overall survival in the CheckMate -816 study underscores the potential of&nbsp;Opdivo&nbsp;in combination with chemotherapy to provide a meaningful survival benefit for patients with resectable NSCLC,&#8221; said Dana Walker, vice president, global program lead, late development, oncology, Bristol Myers Squibb. &#8220;This is the first and only Phase 3 study of a neoadjuvant-only immuno-oncology therapy to show a statistically significant benefit in patients with resectable NSCLC.&#8221;
In October, the FDA approved&nbsp;Bristol Myers&#8217; Opdivo for resectable NSCLC and no known epidermal growth factor&nbsp;receptor mutations or anaplastic lymphoma kinase (ALK) rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy,&nbsp;followed by single-agent&nbsp;Opdivo&nbsp;as adjuvant&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41184042/bristol-myers-10b-cancer-drug-opdivo-scores-expanded-use-fda-approval-for-lung-cancer-in-pre-and-" rel="noreferrer noopener">treatment after surgery</a>.
Last week, Bristol Myers released topline data from its Phase 2 TRANSCEND FL trial of&nbsp;Breyanzi&nbsp;(lisocabtagene maraleucel) for relapsed or refractory indolent B-cell&nbsp;<a target="_blank" href="https://www.benzinga.com/25/02/43597173/whats-going-on-with-bristol-myers-squibb-stock-on-monday" rel="noreferrer noopener">non-Hodgkin lymphoma</a>.
The study met its primary endpoint in the marginal zone lymphoma (MZL) cohort and Breyanzi&nbsp;demonstrated a statistically significant and clinically meaningful overall response rate (ORR) in these patients. It also met the key secondary endpoint of complete response rate (CRR).
Price Action: BMY stock closed higher by 1.01% to $54.98 on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43817229/nisun-international-partners-with-gold-of-china-aiming-30-50-million-gold-market-expansion-in-2025" target="_blank" rel="noreferrer noopener">Nisun Partners With Gold Of China To Tap Booming Market: Details</a></li>
</ul>
Photo via Shutterstock

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">Organon &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGN#NYSE">OGN</a>)</h3>
<ul>
<li>Dividend Yield: 7.24%</li>
<li>Morgan Stanley analyst Terence Flynn maintained an Equal-Weight rating and cut the price target from $17 to $16 on Feb. 14. This analyst has an accuracy rate of 68%.</li>
<li>Piper Sandler analyst David Amsellem maintained an Overweight rating and raised the price target from $22 to $24 on April 29, 2024. This analyst has an accuracy rate of 71%.</li>
<li>Recent News: On Feb. 13, Organon reported better-than-expected fourth-quarter adjusted EPS results.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021925&amp;t=be2bearmibe3na1">OGN news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021925&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="842" height="767" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19080423/image-163.png" alt="" class="wp-image-788843" style="width:573px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19080423/image-163.png 842w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19080423/image-163-300x273.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19080423/image-163-768x700.png 768w" sizes="(max-width: 842px) 100vw, 842px" /></a></figure>
<h3 class="wp-block-heading">Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)</h3>
<ul>
<li>Dividend Yield: 6.73%</li>
<li>Guggenheim analyst Vamil Divan reiterated a Buy rating with a price target of $33 on Feb. 10, 2025. This analyst has an accuracy rate of 76%.</li>
<li>Citigroup analyst Andrew Baum maintained a Neutral rating and cut the price target from $30 to $29 on Jan. 28, 2025. This analyst has an accuracy rate of 70%.</li>
<li>Recent News: On Feb. 13, Pfizer reported Phase 3 TALAPRO-2 study results.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021925&amp;t=be2bearmibe3na1">PFE news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021925&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="907" height="831" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19080512/image-164.png" alt="" class="wp-image-788845" style="width:676px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19080512/image-164.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19080512/image-164-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19080512/image-164-768x704.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
<h3 class="wp-block-heading">Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)</h3>
<ul>
<li>Dividend Yield: 4.56%</li>
<li>Wells Fargo analyst Mohit Bansal maintained an Equal-Weight rating and raised the price target from $60 to $62 on Feb. 7, 2025. This analyst has an accuracy rate of 72%.</li>
<li>Citigroup analyst Andrew Baum maintained a Neutral rating and boosted the price target from $60 to $65 on Jan. 28, 2025. This analyst has an accuracy rate of 70%.</li>
<li>Recent News: On Feb. 19, Bristol Myers Squibb announced the final analysis of overall survival from the Phase 3 Checkmate -816 study, which evaluated Opdivo (Nivolumab) in combination with platinum-doublet chemotherapy as a neoadjuvant treatment for adult patients with resectable (Tumors ≥ 4 cm or node positive) non-small cell lung cancer.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021925&amp;t=be2bearmibe3na1">BMY news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021925&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="905" height="840" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19080554/image-165.png" alt="" class="wp-image-788846" style="width:696px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19080554/image-165.png 905w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19080554/image-165-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19080554/image-165-768x713.png 768w" sizes="(max-width: 905px) 100vw, 905px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43776863/top-3-risk-off-stocks-which-could-rescue-your-portfolio-this-quarter-3">Top 3 Risk Off Stocks Which Could Rescue Your Portfolio This Quarter</a></li>
</ul>

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields

Bristol Myers Squibb Announced The Final Analysis Of Overall Survival From The Phase 3 Checkmate -816 Study, Which Evaluated Opdivo (Nivolumab) In Combination With Platinum-doublet Chemotherapy As A Neoadjuvant Treatment For Adult Patients With Resectable (Tumors ≥ 4 Cm Or Node Positive) Non-small Cell Lung Cancer

Former U.S. Secretary of Labor Robert Reich has called out the tax reduction plans of the Donald Trump-led administration in an X post, terming them as an &#8220;absolutely shameless giveaway,&#8221; that could shoot up the deficit by $4.6 trillion.
What Happened: The possible tax cuts for rich individuals and lower corporate tax rates are likely to widen the U.S. trade deficit, which the Trump 2.0 administration would most likely fund from the tariffs imposed on its trading partners.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Trump wants to extend his tax cuts for rich individuals, which would add $4.6T to the deficit. But he wants to go even further, cutting the corporate tax rate to 15%. It&#39;s yet another absolutely shameless giveaway. <a href="https://t.co/mkAWOFkkUd">pic.twitter.com/mkAWOFkkUd</a>
&mdash; Robert Reich (@RBReich) <a href="https://twitter.com/RBReich/status/1891623719304339516?ref_src=twsrc%5Etfw">February 17, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The data from the Center For American Progress Action Fund or CAPAF shows that cutting the corporate tax rate down to 15% would save all sectors and companies billions of dollars in tax.
<ul>
<li>Top 100 U.S. Companies: Can expect a total annual tax cut of $48 billion despite reporting $1.1 trillion in profits in their 2023 annual report.</li>
</ul>
<ul>
<li>Top 10 U.S. Companies: Reported more than $520 billion in profits according to their 2023 annual report can expect an annual tax cut of $23 billion. These include firms like Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Comcast Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>), and JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>).</li>
</ul>
<ul>
<li>Oil: The five largest U.S. oil companies, including Exxon Mobil Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>), Chevron Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>), Marathon Petroleum Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPC#NYSE">MPC</a>), Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>), and Valero Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLO#NYSE">VLO</a>) will receive an estimated $2.2 billion annual tax cut, despite over $80 billion in profits.</li>
</ul>
<ul>
<li>Pharma: The five largest U.S. drug makers, Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), Merck &amp; Co Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) and Bristol-Myers Squibb Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) will receive an estimated $3.1 billion annual tax cut, despite over $50 billion in profits.</li>
</ul>
<ul>
<li>Banking: The five largest Wall Street banks, JPMorgan Chase, Bank of America Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>), Citigroup Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>), Wells Fargo &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) and Goldman Sachs Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) will receive an estimated $4.1 billion annual tax cut, despite nearly $113 billion in profits.</li>
</ul>
<ul>
<li>Grocery: The five largest grocery companies, Kroger Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>), Costco Wholesale Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>), Albertsons Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACI#NYSE">ACI</a>), Target Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) and Walmart Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) will receive an estimated $1.7 billion annual tax cut, despite over $29 billion in profits.</li>
</ul>
See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/43763438/trump-acting-like-a-mafia-don-says-this-economist-as-uncertainty-mounts-businesses-hold-back-in-fear-of-unforeseen-economic-shifts">Trump &#8216;Acting Like A Mafia Don,&#8217; Says This Economist As Uncertainty Mounts, Businesses Hold Back In Fear Of Unforeseen Economic Shifts</a>
Why It Matters: Trump has threatened all its trading partners with &#8220;reciprocal tariffs,&#8221; while already having implemented 25% on steel and aluminum imports.
According to economists like Craig Shapiro, who is a macro strategist at the Bear Traps Report, tariffs are the "<a href="https://www.benzinga.com/25/02/43587245/tariffs-are-the-only-way-to-fund-tax-cuts-without-deficit-expansion-argues-expert-as-it-takes-center-stage-in-donald-trumps-economic-plan">only way</a>" to fund tax cuts without expanding the federal deficit. 
Shapiro likened Trump&#8217;s governance to that of a &#8220;<a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/43763438/trump-acting-like-a-mafia-don-says-this-economist-as-uncertainty-mounts-businesses-hold-back-in-fear-of-unforeseen-economic-shifts">Mafia Don</a>,&#8221; saying businesses are now uncertain about the economy&#8217;s direction. He noted fading &#8220;initial euphoria&#8221; and a &#8220;wait-and-see&#8221; approach from business leaders due to unclear policies, tariffs, trade agreement uncertainty, and fluctuating government spending. &#8211;
Price Action: On Friday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) which track the S&amp;P 500 and Nasdaq 100 indices, closed mixed. SPY fell 0.0049% to a value of $609.7, and QQQ was up by 0.42% to end at a value of $538.15, according to Benzinga Pro data.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/02/43773441/ahead-of-gamestops-bitcoin-purchase-plans-blackrock-morgan-stanley-goldman-sachs-and-other-billion-dollar-funds-load-up-on-gme-stock-in-q4">Ahead Of GameStop&#8217;s Bitcoin Purchase Plans, BlackRock, Morgan Stanley, Goldman Sachs, And Other Billion Dollar Funds Load Up On GME Stock In Q4</a></li>
</ul>
Photo courtesy: Shutterstock

Equities

Government

Macro Notification

Economics

ABBV

CMCSA

COST

Trump's Tax Cut Could Add $4.6 Trillion To Deficit, With $48 Billion Tax Relief For Top 100 Firms: Robert Reich

No new safety signals observed at Year 5 in the POETYK PSO long-term extension trial, consistent with the established Sotyktu safety profile
Following five years of continuous Sotyktu treatment, clinical response was maintained in nearly half of patients for Psoriasis Area and Severity Index (PASI) 90 in the POETYK PSO long-term extension trial
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bms.com&amp;esheet=54207062&amp;newsitemid=20250216956334&amp;lan=en-US&amp;anchor=Bristol+Myers+Squibb&amp;index=1&amp;md5=d312e4385e5fe1fc51c3a0e3b138ed8e">Bristol Myers Squibb</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) today announced new five-year results from the POETYK PSO long-term extension (LTE) trial of Sotyktu (deucravacitinib) treatment in adult patients with moderate-to-severe plaque psoriasis. The safety profile of Sotyktu remained consistent through five years with more than 5,000 patient-years of exposure in the trial, with no new safety signals identified. In patients who were treated continuously with Sotyktu, clinical response rates were maintained from Year 1 to Year 5, including Psoriasis Area and Severity Index (PASI) 75, PASI 90 and static Physician's Global Assessment (sPGA) 0/1 (clear/almost clear).
These data were presented at the Winter Clinical Dermatology Conference – Hawaii (WCH) in Big Island, Waikoloa Village, HI taking place February 14-19, 2025.

Bristol Myers Squibb Says New 5-Year Sotyktu Data Show Consistent Safety And Durable Response Rates In Moderate-To-Severe Plaque Psoriasis; No New Safety Signals Observed At Year 5 In The POETYK PSO Long-Term Extension Trial, Consistent With The Established Sotyktu Safety Profile

Bristol Myers Squibb Phase 3 RELATIVITY-098 Trial Of Opdualag Did Not Meet Primary endpoint

Whales with a lot of money to spend have taken a noticeably bullish stance on Bristol-Myers Squibb.
Looking at options history for Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) we detected 10 trades.
If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish expectations and 30% with bearish.
From the overall spotted trades, 4 are puts, for a total amount of $160,750 and 6, calls, for a total amount of $225,501.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $50.0 and $60.0 for Bristol-Myers Squibb, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of Bristol-Myers Squibb stands at 1844.57, with a total volume reaching 10,340.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Bristol-Myers Squibb, situated within the strike price corridor from $50.0 to $60.0, throughout the last 30 days.
<h3>Bristol-Myers Squibb Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739386827_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$1.82</td>
<td>$1.74</td>
<td>$1.74</td>
<td>$60.00</td>
<td>$82.6K</td>
<td>3.2K</td>
<td>537</td>
</tr>
<tr>
<td>BMY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/28/25</td>
<td>$0.6</td>
<td>$0.56</td>
<td>$0.6</td>
<td>$53.00</td>
<td>$52.3K</td>
<td>246</td>
<td>969</td>
</tr>
<tr>
<td>BMY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$1.94</td>
<td>$1.85</td>
<td>$1.85</td>
<td>$52.50</td>
<td>$44.0K</td>
<td>4.1K</td>
<td>239</td>
</tr>
<tr>
<td>BMY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/28/25</td>
<td>$0.61</td>
<td>$0.55</td>
<td>$0.6</td>
<td>$53.00</td>
<td>$38.2K</td>
<td>246</td>
<td>969</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/14/25</td>
<td>$0.28</td>
<td>$0.27</td>
<td>$0.28</td>
<td>$57.00</td>
<td>$31.5K</td>
<td>1.9K</td>
<td>3.4K</td>
</tr>
</tbody>
</table>

<h3>About Bristol-Myers Squibb</h3>
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
<h3>Present Market Standing of Bristol-Myers Squibb</h3>
<ul>
<li>With a trading volume of 4,560,473, the price of BMY is down by -0.38%, reaching $55.73.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 71 days from now.</li>
</ul>
<h3>Expert Opinions on Bristol-Myers Squibb</h3>
In the last month, 3 experts released ratings on this stock with an average target price of $60.666666666666664.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Cantor Fitzgerald persists with their Neutral rating on Bristol-Myers Squibb, maintaining a target price of $55. 
&#x2A; Consistent in their evaluation, an analyst from Citigroup keeps a Neutral rating on Bristol-Myers Squibb with a target price of $65. 
&#x2A; An analyst from Wells Fargo has decided to maintain their Equal-Weight rating on Bristol-Myers Squibb, which currently sits at a price target of $62. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Bristol-Myers Squibb with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Bristol-Myers Squibb Unusual Options Activity

Bristol Myers Squibb &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) released topline data Monday from its Phase 2 TRANSCEND FL trial of Breyanzi (lisocabtagene maraleucel) for relapsed or refractory indolent B-cell <a href="https://www.benzinga.com/pressreleases/25/02/b43588330/bristol-myers-squibb-announces-positive-topline-results-for-breyanzi-lisocabtagene-maraleucel-in-a" target="_blank" rel="noreferrer noopener">non-Hodgkin lymphoma</a>.
The study met its primary endpoint in the marginal zone lymphoma (MZL) cohort and Breyanzi demonstrated a statistically significant and clinically meaningful overall response rate (ORR) in these patients. It also met the key secondary endpoint of complete response rate (CRR).
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43528698/bristol-myers-squibb-warns-near-term-impact-due-to-generics-on-2025-sales-forecast-outlines-2-billion-in-additional-cost-cuts" rel="noreferrer noopener">Bristol Myers Squibb Warns Near-Term Impact Due To Generics On 2025 Sales Forecast, Outlines $2 Billion In Additional Cost Cuts</a>
Breyanzi demonstrated durable responses and a consistent safety profile with no new safety signals observed.
This study marks the fifth cancer type in which&nbsp;Breyanzi&nbsp;has demonstrated clinically meaningful benefit.
In May, the FDA approved Breyanzi for relapsed or refractory mantle cell lymphoma (MCL) for patients who received at least two prior<a href="https://www.benzinga.com/general/biotech/24/05/39118061/fda-expands-approval-for-bristol-myers-squibbs-breyanzi-making-car-t-cell-therapy-available-for-b" target="_blank" rel="noreferrer noopener"> lines of systemic therapy</a>.
This FDA approval marks the fourth distinct subtype of non-Hodgkin lymphoma for which Breyanzi is approved, making it the CAR T cell therapy available to treat the broadest array of B-cell malignancies.
Soon after, the FDA granted accelerated approval to Breyanzi for relapsed or&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38877563/fda-approves-expanded-use-of-bristol-myers-squibbs-breyanzi-cancer-cell-therapy-for-previously-tr" rel="noreferrer noopener">refractory follicular lymphoma</a>.&nbsp;
In 2024, Breyanzi sales more than <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43523532/bristol-myers-squibb-reports-fourth-quarter-and-full-year-financial-results-for-2024" rel="noreferrer noopener">doubled to $747 million</a>.
In 2024, U.S. District Judge Jesse Furman of the U.S. District Court for the Southern District of New York dismissed a $6.4 billion lawsuit against issuer Bristol-Myers Squibb. The plaintiff, UMB Bank, had not been properly appointed as the trustee for the securities and therefore lacked standing to sue on behalf of the directing holders.
The issue undermined the lawsuit, filed 17 months after Bristol Myers acquired Celgene <a target="_blank" href="https://www.benzinga.com/24/11/42012040/bristol-myers-faces-renewed-67-billion-lawsuit-over-drug-approval-delays-amid-resolved-trustee-issue" rel="noreferrer noopener">for $80.3 billion in 2019</a>.
Price Action: BMY stock is down 2.87% at $55.22 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/02/43592651/boeing-seeks-more-orders-before-committing-to-indian-aircraft-assembly-line" target="_blank" rel="noreferrer noopener">Boeing Seeks More Orders Before Committing To Indian Aircraft Assembly Line</a></li>
</ul>
Photo: Shutterstock

What's Going On With Bristol Myers Squibb Stock On Monday?

WIIM

Bristol-Myers Squibb shares are trading lower. The company announced Phase 2 TRANSCEND FL trial evaluating Breyanzi in adult patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma.

Bristol Myers Reports Topline Results for Breyanzi In Adult Patients With Relapsed or Refractory Marginal Zone Lymphoma; Trial Met Primary Endpoint Of Overall Response Rate And Key Secondary Endpoint Of Complete Response Rate

Wells Fargo analyst Mohit Bansal maintains Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) with a Equal-Weight and raises the price target from $60 to $62.

Wells Fargo Maintains Equal-Weight on Bristol-Myers Squibb, Raises Price Target to $62

U.S. stocks could open on a mixed note on Friday after the averages closed at a record high on Thursday. Futures of major indices were down, while the Dow was marginally higher.
Newell Brands Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWL#NASDAQ">NWL</a>), Flowers Foods Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLO#NYSE">FLO</a>), and Plains All American Pipeline L.P. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAA#NASDAQ">PAA</a>) are among the companies that will report their earnings today.
The 10-year Treasury yield stood at 4.43%, while the two-year yield was at 4.23%. According to the CME Group&#8217;s FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a>, there is an 85.5% chance that the Federal Reserve will keep interest rates unchanged for the March meeting.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-0.069%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.033%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.033%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.10%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Thursday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) fell 0.006% to $606.28 and the Invesco QQQ ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) declined 0.028% to $529.45, according to<a href="https://benzinga.grsm.io/lxquj26b2sag"> Benzinga Pro data</a>.
Cues From Last Session:
U.S. stocks closed on a mixed note on Thursday, with the S&amp;P 500 and the Nasdaq registering modest gains, while the Dow recorded a marginal decline. Consumer staples, information technology, and financial sectors recorded gains on Thursday, while energy and healthcare stocks closed lower.
On Thursday, Bristol Myers Squibb &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) posted better-than-expected results for its fourth quarter but issued a weak outlook, resulting in a decline of around 4%. Skyworks Solutions Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>) shares dipped around 25% after the company issued second-quarter adjusted EPS guidance below estimates.
On the economic front, U.S. initial jobless claims increased by 11,000 from the previous week to 219,000 in the final week of January, higher than market expectations of 213,000.
The U.S. unit labor costs increased 3% in the fourth quarter following a 0.5% gain in the third quarter.&nbsp; The nonfarm business sector labor productivity increased by 1.2% in the fourth quarter compared to a revised gain of 2.3% in the third quarter.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>0.51%</td>
<td>19,791.99</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.36%</td>
<td>6,083.57</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.28%</td>
<td>44,747.63</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.39%</td>
<td>2,307.12</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts
Sonu Varghese, VP global Macro Strategist at Carson Global, allayed concerns that the U.S. government jobs cut undertaken by Tesla Inc. CEO Elon Musk-led Department of Government Efficiency (DOGE) will hamper the labor market.
"Irrespective of what happens, or does not happen, the turnover in federal government payrolls is going to be tiny compared to what's happening in the overall labor market," he said.
He added that even if the Trump administration laid off everyone except those in Veteran Affairs and crucial defense-related areas, the churn would still be 1.2 million workers – less than an average of 3.4 million workers who quit jobs every month during the fourth quarter.
Upcoming Economic Data
Here's what investors will keep an eye on Friday:
<ul>
<li>The U.S. employment, unemployment, and hourly wages report for January will be out at 8:30 a.m., ET.</li>
<li>Fed Governor Michelle Bowman will speak at 9:25 a.m., ET.</li>
<li>December's wholesale inventory data will be announced at 10:00 a.m., ET.</li>
<li>January's preliminary consumer sentiment data will be out at 10:00 a.m., ET.</li>
<li>December's consumer credit will be released at 3:00 p.m., ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) shares fell over 3% in pre-market amid mixed earnings and Amazon Web Services missing analyst estimates.</li>
<li>Pinterest Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>) shares ripped over 22% as its earnings beat analyst estimates and bright growth outlook.</li>
<li>Affirm Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) shares surged over 16% after the company swung back to profitability and posted a revenue surge.</li>
<li>Take-Two Interactive Software Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>) shares gained nearly 6% as Goldman Sachs analysts raised the price target for the stock after the company posted healthy revenue growth and delivered a positive outlook.</li>
<li>Investors are awaiting earnings results from Newell Brands Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWL#NASDAQ">NWL</a>), Flowers Foods, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLO#NYSE">FLO</a>), and Plains All American Pipeline, L.P. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAA#NASDAQ">PAA</a>) today.</li>
</ul>
Commodities, Gold And Global Equity Markets:
Crude oil futures were trading higher in the early New York session by 0.76% to hover around $71.14 per barrel.
The gold spot index was up by 0.34% to $2,866.30 per ounce. The Dollar Index was up 0.08% at 107.77 level.
Asian markets were trading mixed on Friday. China&#8217;s CSI 300, Hong Kong&#8217;s Hang Seng index advanced, while Australia&#8217;s ASX 200, Japan&#8217;s Nikkei 225, and South Korea&#8217;s Kospi declined. European markets were also mixed.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43553998/sp-500-gains-for-3rd-session-investor-sentiment-improves-but-greed-index-remains-in-fear-zone">S&amp;P 500 Gains For 3rd Session: Investor Sentiment Improves, But Greed Index Remains In &#8216;Fear&#8217; Zone</a></li>
</ul>
Photo courtesy: Shutterstock

AFRM

AMZN

PINS

SWKS

TTWO

US Stocks Likely To Open On A Mixed Note: Amazon, Pinterest, Take-Two Among Stocks To Watch

The CNN Money Fear and Greed index showed some improvement in the overall market sentiment, while the index remained in the &#8220;Fear&#8221; zone on Thursday.
U.S. stocks settled mixed on Thursday, with the S&amp;P 500 recording gains for a third consecutive session.
On Thursday, Bristol Myers Squibb &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) posted better-than-expected results for its fourth quarter but issued a weak outlook. Skyworks Solutions Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>) shares dipped around 25% on Thursday after the company issued second-quarter adjusted EPS guidance below estimates.
Multiple analysts downgraded the stock on Thursday. Shares of Ford Motor Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) fell more than 7% after the company said that it expects $5 billion to $5.5 billion in losses in its EV segment this year, in line with the loss recorded last year.
On the economic data front, U.S. initial jobless claims increased by 11,000 from the previous week to 219,000 in the final week of January, compared to market estimates of 213,000. U.S. unit labor costs rose 3.0% in the fourth quarter following a 0.5% gain in the third quarter. U.S. nonfarm business sector labor productivity rose by 1.2% in the fourth quarter compared to a revised gain of 2.3% in the previous quarter.
Most sectors on the S&amp;P 500 closed on a positive note, with consumer staples, information technology, and financial stocks recording gains on Thursday. However, energy and healthcare stocks bucked the overall market trend, closing the session lower.
The Dow Jones closed higher by over 125 points to 44,747.63 on Thursday. The S&amp;P 500 rose 0.36% to 6,083.57, while the Nasdaq Composite climbed 0.51% to 19,791.99 during Thursday's session.
Investors are awaiting earnings results from Newell Brands Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWL#NASDAQ">NWL</a>), Flowers Foods, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLO#NYSE">FLO</a>), and Plains All American Pipeline, L.P. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAA#NASDAQ">PAA</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 41.1, the index remained in the &#8220;Fear&#8221; zone on Thursday, versus a prior reading of 40.6.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43526669/jim-cramer-says-dont-buy-this-financial-stock-at-this-level-let-it-come-in">Jim Cramer Says Don&#8217;t Buy This Financial Stock At This Level: &#8216;Let It Come In&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Earnings

S&P 500 Gains For 3rd Session: Investor Sentiment Improves, But Greed Index Remains In 'Fear' Zone

It's a mixed session on Wall Street, with major indices struggling for direction as investors hold their breath ahead of a key jobs report <a href="https://www.benzinga.com/markets">set for Friday morning.</a>
The S&amp;P 500 and the Nasdaq 100 edged up 0.3%, while the Dow Jones slipped 0.1% and small caps held steady.
Among the leading sectors, financial stocks outperformed after the Fed released the framework for 2025 bank stress test. The big six banks — JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>), Bank of America Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>), Wells Fargo &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>), Goldman Sachs Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>), Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>), and Citigroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>) — all climbed more than 1%, with Citigroup surging 2.9%.
Eli Lilly Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) jumped 3.2% after topping earnings estimates, while Tapestry Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>) surged 12% and Philip Morris International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>) skyrocketed nearly 10% on strong revenue figures. In contrast, Qualcomm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) slid 4.3% on concerns over slowing smartphone demand.
Shares of Palantir Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) surged 6.5%, extending its weekly gains to 30.8%, the stock's best weekly rally since early November.
Oil prices had a volatile session. Crude initially dipped as speculation mounted over a potential Trump-Putin meeting as early as this month or next, raising hopes for possible peace talks in Ukraine. Prices rebounded after the U.S. Treasury imposed sanctions on Iran's oil network.
Gold softened, dropping 0.6% from record highs and snapping a five-session winning streak.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) remained stable, hovering just below $97,000.
<h2 class="wp-block-heading">Thursday&#8217;s Performance In Major US Indices, ETFs</h2>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,742.18</td>
<td>0.4%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,082.15</td>
<td>0.3%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,316.14</td>
<td>0.0%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>44,811.50</td>
<td>-0.1%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 1:00 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)&nbsp;rose 0.3% to $605.83.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) eased 0.2% to $447.73.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;inched 0.3% up to $528.47.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) flattened at $229.55.</li>
<li>The&nbsp;Financial Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>) outperformed, up 1.6%; the&nbsp;Energy Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) lagged, down 1.7%.</li>
</ul>
<h3 class="wp-block-heading">Thursday&#8217;s Stock Movers</h3>
Stocks reacting to corporate earnings, ordered by market capitalization, are:
<ul>
<li>Eli Lilly &amp; Co.: up 3.11%</li>
<li>Linde Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LIN#NYSE">LIN</a>): up 0.34%</li>
<li>Philip Morris International Inc.: up 9.97%</li>
<li>Honeywell International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>): down 5.33%</li>
<li>ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>): down 0.71%</li>
<li>Hilton Worldwide Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLT#NYSE">HLT</a>): up 4.65%</li>
<li>Bristol-Myers Squibb Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>): down 2.04%</li>
<li>Intercontinental Exchange Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ICE#NYSE">ICE</a>): up 4.95%</li>
<li>IQVIA Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>): up 2.95%</li>
<li>Yum! Brands Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUM#NYSE">YUM</a>): up 8.49%</li>
<li>Hershey Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>): up 5.16%</li>
<li>McKesson Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>): down 2.56%</li>
<li>Qualcomm Inc.: down 4.41%</li>
<li>Molina Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>): down 8.68%</li>
<li>O&#8217;Reilly Automotive Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORLY#NASDAQ">ORLY</a>): down 1.87%</li>
<li>MetLife Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MET#NYSE">MET</a>): down 1.39%</li>
<li>Cognizant Technology Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSH#NASDAQ">CTSH</a>): up 3.64%</li>
<li>Corteva Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTVA#NYSE">CTVA</a>): down 3.92%</li>
<li>Allstate Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALL#NYSE">ALL</a>): down 0.07%</li>
<li>Skyworks Solutions Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>): down 23.74%</li>
<li>Aflac Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AFL#NYSE">AFL</a>): down 3.64%</li>
<li>Align Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>): down 0.66%</li>
<li>Equifax Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFX#NYSE">EFX</a>): down 6.24%</li>
<li>Zimmer Biomet Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>): down 3.02%</li>
<li>Aptiv Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APTV#NYSE">APTV</a>): up 4.18%</li>
<li>Air Products &amp; Chemicals Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APD#NYSE">APD</a>): down 1.75%</li>
<li>Kellanova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/K#NYSE">K</a>): up 0.12%</li>
<li>Ford Motor Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>): down 6.74%</li>
</ul>
Stocks reporting after the close include: 
<ul>
<li>Amazon.com Inc. </li>
<li>Illumina Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>)</li>
<li>Fortinet Inc.</li>
<li>Expedia Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>)</li>
<li>Take-Two Interactive Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>)</li>
<li>Monolithic Power Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>)</li>
<li>Pinterest Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>)</li>
<li>SS&amp;C Technologies Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSNC#NASDAQ">SSNC</a>)</li>
<li>Principal Financial Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFG#NASDAQ">PFG</a>)</li>
<li>Mettler-Toledo International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTD#NYSE">MTD</a>)</li>
<li>AptarGroup Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATR#NYSE">ATR</a>)</li>
<li>Post Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POST#NYSE">POST</a>)</li>
<li>Mohawk Industries Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MHK#NYSE">MHK</a>)</li>
<li>Boyd Gaming Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYD#NYSE">BYD</a>)</li>
<li>Encompass Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EHC#NYSE">EHC</a>)</li>
<li>VeriSign Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSN#NASDAQ">VRSN</a>)</li>
<li>Cloudflare Inc. </li>
<li>Skechers USA Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>)</li>
<li>Affirm Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>)</li>
<li>Elf Beauty Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>)</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43534297/january-jobs-report-preview-speculators-bet-on-strong-payroll-surge-yet-economists-predict-a-different-picture">January Jobs Report Preview: Speculators Bet On Strong Payroll Surge, Yet Economists Predict A Different Picture</a></li>
</ul>
Photo via Shutterstock.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Broad U.S. Equity ETFs

Commodities

Econ #s

ETFs

$BTC

ALGN

APTV

CTSH

CTVA

SPDR Dow Jones Industrial Average ETF Trust

EXPE

ILMN

MPWR

ORLY

PLTR

POST

QCOM

SSNC

VRSN

XLRE

Stocks Edge Higher, Bank Giants Rally, Palantir Skyrockets: What's Driving Markets Thursday?

Live On CNBC, Josh Brown Announces Sold Bristol-Myers Squibb

U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 150 points on Thursday.
The Dow traded down 0.35% to 44,715.15 while the NASDAQ rose 0.08% to 19,708.01. The S&amp;P 500 also rose, gaining, 0.14% to 6,069.88.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43493237/jim-cramer-this-health-care-stock-is-a-winner-buy-bitcoin-instead-of-coinbase">Jim Cramer: This Health Care Stock Is A &#8216;Winner,&#8217; Buy Bitcoin Instead Of Coinbase</a>
Leading and Lagging Sectors Financials shares surged by 0.7% on Thursday.
In trading on Thursday, energy shares fell by 1.4%.
Top Headline
On Thursday, Bristol Myers Squibb &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) posted better-than-expected results for its fourth quarter, but issued weak outlook.
The company posted fourth-quarter revenues of $12.34 billion, beating the consensus of $11.57 billion. The company reported an adjusted EPS of $1.67, down from $1.70 a year ago, beating the consensus of $1.46.
Bristol Myers Squibb said it sees 2025 adjusted EPS of $6.55-$6.85 compared to the consensus of $6.92. The company forecasts 2025 sales of $45.5 billion versus the consensus of $46.27 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Lipella Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIPO#NASDAQ">LIPO</a>) shares shot up 86% to $4.90 after the company received FDA approval for an expanded access program for LP-310 in oral lichen planus.</li>
<li>Shares of American Superconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMSC#NASDAQ">AMSC</a>)got a boost, surging 31% to $33.40 after the company reported better-than-expected third-quarter financial results and issued fourth-quarter sales guidance with its midpoint above estimates.</li>
<li>Digital Turbine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPS#NASDAQ">APPS</a>) shares were also up, gaining 86% to $4.7250 after the company reported better-than-expected third-quarter financial results and raised its FY25 sales guidance.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Skyworks Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>) shares dropped 24% to $66.33 after the company issued second-quarter adjusted EPS guidance below estimates. Multiple analysts downgraded the stock on Thursday.</li>
<li>Shares of Sensus Healthcare, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRTS#NASDAQ">SRTS</a>) were down 29% to $6.36 after the company reported mixed fourth-quarter financial results.</li>
<li>WEX Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WEX#NYSE">WEX</a>) was down, falling 17% to $155.07 after the company issued first-quarter and FY25 guidance below estimates.</li>
</ul>
Commodities In commodity news, oil traded up 0.5% to $71.36 while gold traded down 0.8% at $2,869.50.
Silver traded down 1.7% to $32.420 on Thursday, while copper fell 0.4% to $4.4275.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 1.08%, Germany's DAX 40 gained 1.22% and France's CAC 40 rose 1.40%. Spain's IBEX 35 Index rose 1.30%, while London's FTSE 100 rose 1.37%.
Asia Pacific Markets
Asian markets closed mostly higher on Thursday, with Japan's Nikkei 225 gaining 0.61%, China's Shanghai Composite Index climbing 1.27%, Hong Kong's Hang Seng Index gaining 1.43% and India's BSE Sensex falling 0.27%.
Economics
<ul>
<li>U.S. initial jobless claims increased by 11,000 from the previous week to 219,000 in the final week of January, compared to market estimates of 213,000.</li>
<li>U.S. unit labor costs rose 3.0% in the fourth quarter following a 0.5% gain in the third quarter.</li>
<li>U.S. nonfarm business sector labor productivity rose by 1.2% in the fourth quarter compared to a revised gain of 2.3% in the previous quarter.</li>
<li>U.S. employers announced job cuts of 49,795 in January up from 38,792 in the previous month.</li>
<li>U.S. natural gas stocks fell 174 billion cubic feet in the week ending Jan. 31.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/02/43527663/wall-streets-most-accurate-analysts-weigh-in-on-3-tech-stocks-delivering-high-dividend-yields-2">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Tech Stocks Delivering High Dividend Yields</a></li>
</ul>

Eurozone

Intraday Update

AMSC

APPS

LIPO

SRTS

Dow Dips 150 Points; Bristol Myers Squibb Issues Weak Outlook

On Thursday,&nbsp;Bristol Myers Squibb &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) posted fourth-quarter revenues of $12.34 billion, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $11.57 billion</a>.
Sales increased 8% year-over-year, or 9% when adjusted for foreign exchange impacts, primarily driven by the Growth Portfolio and higher demand for Eliquis, partially offset by the impact of generics on Sprycel, Revlimid, Abraxane&nbsp;and&nbsp;Pomalyst.
Growth Portfolio worldwide revenues increased to $6.36 billion, representing growth of 21% on a reported basis or 23% when adjusted for&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43523532/bristol-myers-squibb-reports-fourth-quarter-and-full-year-financial-results-for-2024" rel="noreferrer noopener">foreign exchange impacts</a>.
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/24/12/42638844/large-biopharma-lags-market-jp-morgans-2025-outlook-on-eli-lilly-merck-and-more" rel="noreferrer noopener">Big Biopharma Trails Behind The Market: JP Morgan&#8217;s 2025 Outlook on Eli Lilly, Merck, and More</a>
Opdivo sales increased 4% to $2.48 billion. The arthritis drug Orencia generated sales of $1 billion, up 2%. Sales of another cancer drug, Yervoy, increased 19% to $675 million.
Anemia drug Reblozyl generated $547 million in the quarter sales, up 71% from a year ago. Revenues for the Legacy Portfolio were $5.98 billion, down 4%.
The company reported an adjusted EPS of $1.67, down from $1.70 a year ago, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $1.46</a>.
Bristol Myers Squibb expanded its existing strategic productivity initiative to include approximately $2 billion in additional annualized cost savings by the end of 2027.
In the third quarter of 2024, the company outlined cost-saving initiatives and anticipated&nbsp;internal cost savings of <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41655052/bristol-myers-squibb-boosts-2024-outlook-on-strong-demand-for-blood-thinner-med-new-drugs-drive-q" rel="noreferrer noopener">around $1.5 billion in 2025</a>.
Guidance:&nbsp;Bristol Myers Squibb forecasts 2025 adj EPS of $6.55-$6.85 compared to the consensus of $6.92. The company forecasts 2025 sales of $45.5 billion versus the consensus of $46.27 billion.
The U.S. pharma giant estimates revenue forecast reflects, as previously expected, the near-term impact of generics across Revlimid,&nbsp;Pomalyst, Sprycel&nbsp;and&nbsp;Abraxane, which is expected to result in a revenue decline of approximately 18-20% of the Legacy Portfolio.
This is expected to be partially offset by the continued strength of the Growth Portfolio. This guidance also reflects an approximate $500 million expected negative impact to revenue due to foreign exchange.
Price Action: At the last check on Thursday, BMY stock was down 4.04% to $57.30.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43526541/honeywell-q4-earnings-revenue-and-eps-beat-pursues-planned-split-into-3-public-companies-by-2026" target="_blank" rel="noreferrer noopener">Honeywell Q4 Earnings: Revenue And EPS Beat, Pursues Planned Split Into 3 Public Companies By 2026</a></li>
</ul>
Image via Bristol-Myers Squibb

Guidance

Bristol Myers Squibb Warns Near-Term Impact Due To Generics On 2025 Sales Forecast, Outlines $2 Billion In Additional Cost Cuts

We estimate total revenues to be approximately $45.5 billion, reflecting, as previously expected, the near-term impact of generics across Revlimid, Pomalyst, Sprycel and Abraxane, which we expect to result in a revenue decline of approximately 18-20% of the Legacy Portfolio. This is expected to be partially offset by the continued strength of our Growth Portfolio. This guidance also reflects an approximate $500 million expected negative impact to revenue due to foreign exchange.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="2" rowspan="1">2025 Non-GAAP1 Line-Item Guidance</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total Revenues&nbsp; (Reported &amp; Ex-F/X)</td>
<td colspan="1" rowspan="1">~$45.5 billion</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Gross Margin %</td>
<td colspan="1" rowspan="1">~72%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Operating Expenses2</td>
<td colspan="1" rowspan="1">~$16 billion</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Other Income/(Expense)</td>
<td colspan="1" rowspan="1">~$30 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Tax Rate</td>
<td colspan="1" rowspan="1">~18%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Diluted EPS</td>
<td colspan="1" rowspan="1">$6.55-$6.85</td>
</tr>
</tbody>
</table>
</figure>

Bristol-Myers Squibb FY25 Outlook: Adj EPS $6.55-$6.85 vs $6.92 Est; Sales $45.500B vs $46.27B Est

Press Releases

Demand for Advanced Pancreatic Cancer Treatments at All Time High as Promising Options Come into Focus

Bristol Myers Squibb Presents Results from CheckMate -8HW Analysis Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) Compared to Opdivo Monotherapy...

Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma

Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma

Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024

Bristol Myers Squibb Announces Positive Topline Results for Breyanzi® (lisocabtagene maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma

Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial

New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis

Bristol Myers Squibb Announces Opdivo® Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall Survival in Resectable Non-Small Cell Lung Cancer

BioArctic's global license agreement with Bristol Myers Squibb for PyroGlutamate-amyloid-beta antibody program effective after antitrust clearance and closing

GILD

ONCY

TSX:ONC

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Comments

Bristol-Myers Squibb

Unusual Options Activity for

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga